SciSparc’s MitoCareX Merger with N2OFF Approved by Shareholders
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from SciSparc Ltd. ( (SPRC) ) is now available.
On September 25, 2025, N2OFF shareholders approved the merger with SciSparc’s majority-owned subsidiary, MitoCareX, which focuses on drug discovery for resistant cancers like pancreatic and non-small cell lung cancer. This merger will make MitoCareX a wholly owned subsidiary of N2OFF, with financial commitments to support its operations. The transaction is expected to close in early October 2025, subject to remaining conditions, and involves significant stock exchanges and financial arrangements, impacting both companies’ strategic positioning in the cancer therapeutics market.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company that focuses on developing therapies for central nervous system disorders. The company is engaged in drug development programs based on cannabinoid pharmaceuticals, including treatments for Tourette Syndrome, Alzheimer’s disease, ASD, and status epilepticus. SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 4,095,711
Technical Sentiment Signal: Sell
Current Market Cap: $2.38M
See more insights into SPRC stock on TipRanks’ Stock Analysis page.
